Company’s decision to lengthen lipid lowering trial causes controversyBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39545.529028.DB (Published 10 April 2008) Cite this as: BMJ 2008;336:797
- Jeanne Lenzer
The decision to extend enrolment of participants in a lipid lowering trial that was set to come to an end in 2011 because the target for enrolments had already been exceeded is causing controversy.
The delay follows an earlier row about the delayed reporting of the results of another study of the same drug, ezetimibe, which is manufactured jointly by Merck and Schering-Plough and sold singly as Ezetrol in the United Kingdom and as Zetia in the United States, or in combination with simvastatin as Inegy in the UK and Vytorin in the US (BMJ 2008;336:180-1; doi: 10.1136/bmj.39468.610775.DB).
Merck and Schering-Plough published a news release on 28 March stating that they will extend enrolment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial